# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MYMD-1® development to continue through fully funded mid-stage clinical trialsClinical study of MYMD-1 in sarcopenia/frailty me...
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system